聚乙二醇化重组人粒细胞刺激因子专项处方点评与分析

Specific Prescription Comments and Analyses of Pegylated Recombinant Human Granulocyte Stimulating Factor

目的:通过实施处方专项点评,了解肿瘤患者PEG-rhG-CSF临床用药情况,发现不适宜用药问题,为指导合理用药提供依据。方法:随机抽取2020年从本院出院并使用PEG-rhGCSF的病例200例,参照相关指南及药品说明书制定点评标准,并依据此标准评价PEG-rhGCSF的用药合理性。结果:在200例中,不合理用药达160例(占80.00%),其中无适应症用药最多(144例,占90.00%),其次为用药剂量偏低(64例,占40.00%)、用药途径不适宜(6例,占3.75%)等。无适应症用药在低FN风险患者中最为常见(135例,占93.75%)。结论:PEG-rhG-CSF临床应用中不合理用药现象较为普遍,尤其对于低FN风险患者中的预防用药缺乏依据,需引起临床重视。

Objective:To understand the clinical drug use of pegylated recombinant human granulocyte stimulating factor(PEG-rhG-CSF)in cancer patients through prescription comments,and to find out problems in drug use and provide a base for guiding clinical rational drug use.Methods:A total of 200 patients who were discharged from our hospital in March 2020 and received PEG-rhG-CSF were randomly selected.The criteria were developed with reference to the relevant guidelines and drug instructions to review the rationality of the use of PEG-rhG-CSF.Results:Among the 200 patients,161(80.00%)had irrational drug use,including irrational indication as the most common(144 cases,90.00%),low dosage(64 cases,40.00%),unsuitable administration course(6 cases,3.75%),unsuitable time of medication(11 cases,6.88%),etc.The most common irrational indication was patients with low FN risks(135 cases,93.75%).Conclusions:The irrational use of PEG-rhG-CSF is common in clinical practice,especially in patients with low FN risks,so clinical attentions should be paid to it.